Screener
Cytek Biosciences, Inc. CTKB EPS (Diluted)
Discontinued — last reported Q2 '26
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Cytek Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare.
The source filing: Cytek Biosciences, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053496
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Numerator | ||||
| Net loss | $(12,158) | $(5,583) | $(31,024) | $(16,985) |
| Denominator | ||||
| Weighted-average common shares outstanding, basic and diluted | 129,460,518 | 126,934,294 | 129,084,814 | 127,632,999 |
| Net loss per share, basic and diluted | $(0.09) | $(0.04) | $(0.24) | $(0.13) |
Item 1. Consolidated Financial Statements (Unaudited)
FAQ
- What is Cytek Biosciences, Inc.'s EPS (diluted)?
- Cytek Biosciences, Inc. (CTKB) reported EPS (diluted) of -$0.09 in Q2 2026.
- How has Cytek Biosciences, Inc.'s EPS (diluted) changed year-over-year?
- Cytek Biosciences, Inc.'s EPS (diluted) decreased by 125.0% year-over-year, from -$0.04 to -$0.09.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Cytek Biosciences, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude